It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Early insights into solid-state properties can shape the entire development journey of your candidate molecule. Our goal is to foster meaningful discussions that help de-risk your compound’s physical form, ensuring a smoother path from discovery to clinic.
With a flexible, tiered approach and the ability to work from just 10 mg of compound, our solid form analysis combines advanced techniques to deliver insights that link physical form to PK interpretation, bioavailability, and manufacturability.
Whether you’re screening early batches or resolving variability in retrospective data, we tailor our characterization to your project’s stage and material constraints.
Understanding the solid form properties of a material can significantly impact other studies. For instance, small-scale batches from chiral SFC might be amorphous and dissolve readily, but process chemistry and scale-up could produce a crystalline form, reducing solubility by up to tenfold. This can lead to inconsistent PK profiles, complicating early data interpretation and affecting in vivo performance.
Monitoring batch-to-batch variability and selecting a stable form early helps avoid formulation-related inconsistencies, ensures reproducibility across studies, and reduces the risk of late-stage setbacks. It lays the foundation for reliable dose escalation and robust safety assessments.
Why Solid Form Matters?
The solid form of a drug candidate is more than just physical state – it’s a key driver of success. Whether crystalline, amorphous, or salt form, each variant can dramatically influence solubility, bioavailability, stability, and manufacturability. These properties affect how the drug behaves in vivo, how it’s formulated, and how reliably it performs across batches.
Early solid form analysis helps uncover risks before they become costly setbacks. It improves interpretation of PK data, supports consistent exposure, and guides formulation strategy. By understanding and controlling solid-state properties from the outset, you set the stage for a more efficient and reliable development journey.
Core Solid Form Analytical Techniques
We offer a tiered approach to solid form characterization, scaling from minimal screening to comprehensive evaluation based on your program needs and available material.
XRPD Analysis
Determine whether the sample is crystalline or amorphous and confirm consistency with previous batches. Useful for identifying form changes in the drug and excipients.
TGA Analysis
Assess thermal stability, hydration and solvation levels, and surface-bound volatiles.
DSC Analysis
Establish melting point and glass transition (Tg); evaluate polymorphic interconversion and enantiotropic/monotropic relationships.
DVS Analysis
Characterize hygroscopicity, hydrate formation and dehydration, and the kinetics of change across humidity conditions.
Microscopy
Examine morphology and particle size distribution; support confirmation of crystallinity.
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
FAQs
Investing in solid form analysis prior to lead candidate selection may appear premature, but it is often a strategically sound decision. At this stage of development, multiple promising molecules are typically under evaluation, and understanding their solid-state behavior can serve as a critical differentiator. Early insights into properties such as solubility, stability, and manufacturability enable prioritization of candidates that are not only pharmacologically effective but also viable for development. Additionally, early analysis can identify potential risks, such as poor crystallinity or polymorphic instability, that may hinder progress later in the pipeline. By incorporating solid form analysis early, you mitigate the risk of selecting a molecule that performs well in theory but fails during formulation or scale-up, ultimately saving time, cost, and resources downstream.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
